Floatz logo

bz019

Primary Mediastinal Large B Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

87 Active assets in the Primary Mediastinal Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
Inno-206
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Inno-206
University of Washington
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

bz019 is also rated in:

large B-cell lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →